Artivion reports fourth quarter and full year 2023 financial results

Fourth quarter and recent business highlights: achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a gaap basis and 15% on a non-gaap constant currency basis achieved revenue of $354.0 million for the full year of 2023 versus $313.8 million for the full year of 2022, an increase of 13% on a gaap basis and 12% on a non-gaap constant currency basis net loss was ($4.0) million or ($0.10) per fully diluted share and non-gaap net income was $4.6 million or $0.11 per fully diluted share in the fourth quarter of 2023 non-gaap adjusted ebitda increased 40% to $15.3 million in the fourth quarter of 2023 compared to $11.0 million in the fourth quarter of 2022. for the full year adjusted ebitda increased 29.5% to $53.8 million generated $11.4 million of free cash flow for the full year of 2023 closed non-dilutive credit agreement for $350.0 million of senior secured, interest-only, credit facilities with 6-year maturities completed enrollment of the amds persevere clinical trial and presented positive results of the full ide cohort at the sts annual meeting demonstrating a significant reduction of all-cause mortality and primary major adverse events (maes) at 30-days following amds implantation appointed lance a.
AORT Ratings Summary
AORT Quant Ranking